ARTICLE | Company News

Cypress, Marina Biotech deal

August 30, 2010 7:00 AM UTC

Cypress acquired Marina's patent rights and technology related to an intranasal formulation of carbetocin. Cypress expects to start Phase II testing in 1Q11 for the long-acting analog of oxytocin to treat autism. Marina will receive $750,000 up front and is eligible for $27 million in milestones, plus single-digit royalties. ...